Abstract The potential for synergistic interactions between anticancer drugs has been used to justify combinations of agents in clinical trials. However, most combinations of targeted agents and chemotherapies have been tested in the clinic without previous systematic evaluation of their potential benefit. Preclinical studies may help in the identification of synergistic or antagonistic interactions. For antineoplastic therapies, these studies may reveal synergy or antagonism of the drug combinations. Synergy occurs when two agents given together produce higher antitumoral activity than the sum of each individual drug. This represents the ideal setting for the development of combinations of targeted agents and chemotherapies. On the other side, certain drug combinations have shown adverse results, indicative of an antagonistic effect. In this article, we review the preclinical molecular bases that justify approved combinations of targeted agents with chemotherapy including examples of synergistic and antagonistic combinations. We also discuss scenarios for rational associations of targeted agents based on biological data and propose strategies that may improve the success of combinations of anticancer agents.
Introduction
The combination of two or more drugs with the aim of obtaining better therapeutic responses is an established approach used to treat several diseases [1, 2] . Examples of successful drug combinations are anti-retroviral agents used for the treatment of the human immunodeficiency virus or antibiotic combinations to treat complex infections. In oncology, drug combinations were first used in the management of hematologic malignancies and then introduced in solid tumors [1] . Even though most combination therapies were initially developed using chemotherapeutic agents, the identification of molecular alterations in cancer opened the possibility of improving the efficacy of antitumoral treatments by combining chemotherapy with targeted agents [1] . While such strategies have demonstrated efficacy and have subsequently reached clinical practice, some combinations using targeted agents have failed to result in clinical benefit or have shown deleterious effects. In this review, we revisit the clinical value of drug combinations using targeted agents, especially when given together with chemotherapy.
Evaluation of effectiveness in drug combination studies
From a clinical perspective, several benefits are expected from drug combinations. The principal benefit is higher antitumoral effect. Other benefits include maintenance of the anticancer effect but with less toxicity resulting from the possibility of reducing the dose of individual drugs or the avoidance of the development of drug resistance.
Antitumoral efficacy is normally first assessed in vitro , where cell lines representative of the disease are tested against antitumoral agents and cell proliferation or cell death is measured [3] . Data obtained from these experiments allows categorization of a drug combination into synergistic, additive, or antagonistic. The concepts of synergy, additivity, and antagonism have been the subject of debate over the last years [4] . In practical terms, when two drugs are combined and the resultant activity is similar to the cumulative action of the individual drugs, the combination is considered additive. Synergy occurs when the action of a drug combination is greater than the expected sum of the activity of each individual agent when given alone (Fig. 1a ) [4] . Clinical benefit may result from combinations where additivity or synergism is observed, but the latter effect is preferred. Antagonism reflects an effect below that expected from the sum of the individual effects.
One of the most widely used algorithms to evaluate drug combinations is the Chou and Talalay method [4] . In this method, various (usually two-drug) combinations are tested. The recommended procedure for this in vitro analysis is to use at least five different dosing combinations, maintaining a fixed ratio between the drugs. Upon analyses of the activity of these different combinations, several parameters which help in establishing whether a drug combination is synergistic, additive, or antagonistic are obtained. The most commonly used parameter is the Combination Index (CI). Combination indices of 1 suggest additivity, while CI <1 indicate synergism, and CI >1 antagonism (Fig. 1b) . In theory, animal-based in vivo experiments can also be performed, but the number of animals needed to get all the points of the dose-effect curve makes this approach less practical, more expensive, and time-consuming, and is not usually performed when evaluating new drug combinations [3] .
Usually, once proof of effectiveness of a certain drug combination is obtained in vitro , animal studies aimed at evaluating antitumoral activity and potential toxicity can be initiated. The most common situation when analyzing drug combinations in animals is the use of a standard of care treatment combined with a novel agent (Fig. 1c) . In these experiments, the dose of the standard of care drug is fixed, and a limited number of doses (usually one or two) of the experimental agent are evaluated. The effect of each agent administered alone has to be assessed adequately to evaluate the antitumoral effect of the combinations as compared to individual agents (Fig. 1c) . In vivo assessment of the antitumoral activity of combinations of two experimental agents can also be performed, but the design of trials of these combinations is more complex than the combination of a standard of care with an experimental agent.
The second expected benefit of a drug combination is to decrease toxicity while maintaining the antitumoral effect. The concept of therapeutic index is based on the principle that the toxicity to normal tissues should be minimal or less than the damage to tumor cells. The development of drug combinations is only feasible if there are additive or synergistic effects against the tumor with less than additive toxicity for normal tissues. Contrary to evaluation of synergism, additivity, and antagonisms that are mostly studied in vitro , the therapeutic index is studied in animal models where normal tissues share physical space with the tumor. Although regulatory authorities do not require preclinical toxicity studies of drug combinations for the initial approval of a clinical study (e.g., Nonclinical Evaluation for Anticancer Pharmaceuticals S9 guideline) (http://www.fda.gov/downloads/Drugs/…/ Guidances/ucm085389.pdf), it is considered good practice to evaluate the effect of pharmacologic active doses of a new drug in animal models in relation to the highest non-severely toxic dose (HNSTD, the highest dose level that does not produce evidence of lethality, life-threatening toxicities, or irreversible findings). Such data could later be extrapolated to doses expected to have similar results in humans thereby providing information on the expected therapeutic index. In addition, plasma concentrations between active and toxic doses in animals should be obtained and compared with active doses in in vitro studies.
The third expected benefit from the drug combinations and which is related to efficacy is the ability to overcome drug resistance. Unfortunately, preclinical models assessing resistance are less well established than models to analyze antitumoral effect. These preclinical models rely on the use of tumor cell lines resistant to a specific therapy. Two types of resistance situations, which mimic the clinical situation, can be observed. Primary resistant cells are those in which the drug is ineffective from the beginning of the treatment. Secondary resistance may be studied in clones of resistant cells, usually obtained upon chronic exposure of a sensitive tumoral cell line to the drug. Another more physiological resistance model can be obtained by in vivo studies. In this context, cell lines sensitive to a drug can be implanted in mice. Upon generation of tumors, detected by either direct inspection or with the help of imaging techniques, the treatment is initiated. Using a continuous schedule of treatment at tolerable doses that permit a long exposure, tumor burden is analyzed and when clear signs of resistance arise, tumors may be excised and analyzed or explanted and replated for in vitro experiments [3] .
Data derived from preclinical studies can therefore provide evidence of the activity of a particular drug combination and help select which standard of care treatment would be best to combine with a given targeted agent. However, evidence of preclinical activity is not a guarantee for clinical activity. Moreover, failure to detect a benefit of a drug combination in preclinical models should also be interpreted with caution, since clinical effectiveness may still occur if the model selected for its evaluation is not appropriate. Examples of the discordance between preclinical and clinical evaluation of drug combinations are reviewed below. 
Agents targeting the transformed cell
Most of the clinically relevant experience on the interactions of targeted agents with chemotherapy in solid tumors has been obtained from studies that analyzed combinations using agents that target the ErbB/HER family of receptors. ErbB/HER receptors and their ligands have been the subject of much investigation due to their predominant presence and activity in several solid tumors such as breast, gastrointestinal, lung, and head and neck cancers [5] [6] [7] [8] . Four ErbB/HER receptors have been identified in mammals: epidermal growth factor receptor (EGFR/HER1/ErbB1), ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4. These receptors are transmembrane molecules endowed with tyrosine kinase activity, which is critical for their pro-oncogenic activity. Agents acting on two of these receptors, the EGFR and HER2, have reached clinical use. Studies on the third member of the family, HER3, have suggested that this receptor has low kinase activity [9] but may be relevant in drug resistance [9, 10] . Furthermore, expression of HER3 has been linked to poor patient outcome in several types of tumors [10] . Moreover, some mutations in HER3 have been associated with certain neoplastic diseases [9] , and its targeting appears to result in therapeutic benefit in preclinical models [9, 11] . For these reasons, clinical studies using anti-HER3 agents have been initiated. Strategies to target ErbB/HER receptors include monoclonal antibodies against the extracellular domain of the receptor and small tyrosine kinase inhibitors (TKIs) designed to inhibit the intracellular kinase [7, 12] . Anti-ectodomain antibodies include trastuzumab or pertuzumab, which target HER2, and cetuximab or panitumumab that target the EGFR (Fig. 2) [7] . Trastuzumab binds to subdomain IV of HER2, while pertuzumab binds to the dimerization arm of HER2 present in subdomain II, impeding interaction of HER2 with other HER family receptors [5] . Cetuximab and panitumumab interact with regions of subdomain III of the EGFR which influence ligand binding [7] . TKIs like lapatinib, against EGFR and HER2, or more specific anti-EGFR inhibitors such as gefitinib or erlotinib have also been developed ( Fig. 2) [7, 13] . Currently, irreversible TK inhibitors against EGFR and HER2 such as Afatinib (BIBW2992, Boehringer, Ingelheim), Neratinib (HKI-272, Puma Biotechnology, Los Angeles), and AZD8931 (AstraZeneca, Stockport, UK) are in clinical development in different solid tumors [12] . Below, we describe the clinically relevant combinations of chemotherapy with agents that target these receptors, based on the mechanism of action of the chemotherapy used (see also Table 1 ).
Agents that act on DNA
Platinum compounds and radiotherapy mediate their antitumor activity by directly provoking damage to DNA, including interstrand cross-links, DNA-protein cross-links, or DNA breaks ( Fig. 2 ) [14] . Several preclinical studies have indicated that antibodies or TKIs against ErbB/HER receptors enhance the antitumor activity of treatments that directly target DNA. For instance, inhibition of EGFR with erlotinib or cetuximab attenuates DNA repair mechanisms [15] [16] [17] [18] [19] [20] . Administration of trastuzumab in combination with cisplatin delayed repair of the DNA interstrand cross-links, which translated into a synergistic interaction [21] . In colon cancer, cetuximab reduced the expression of DNA repair proteins and augmented the antitumoral action of oxaliplatin [22] .
The value of these preclinical findings has been explored in the clinic. In gastric cancer, a study demonstrated the clinical benefit of trastuzumab in addition to cisplatin-based chemotherapy [23] . In non-small cell lung cancer, cetuximab synergistically augmented the antitumoral action of cisplatin in cells sensitive to cetuximab [24] . In the clinical setting, this drug combination was more effective than chemotherapy alone [24, 25] . However, in metastatic breast cancer, trastuzumab in the addition of platinum compounds did not augment the effect of docetaxel and trastuzumab [26, 27] .
Topoisomerase inhibitors: irinotecan and doxorubicin
Irinotecan is a topoisomerase I inhibitor that prevents both DNA replication and transcription [28] . In colon cancer cell lines and xenografted tumors, the combination of cetuximab with irinotecan enhanced the antitumoral action of irinotecan alone [29] . Subsequently, this combination was developed clinically [30, 31] . Doxorubicin interacts with DNA by intercalation, and inhibits DNA relaxation, preventing the progression of the enzyme topoisomerase II [28] . Combination of trastuzumab or other anti-ErbB/HER antibodies with doxorubicin increased the efficacy of this drug in several tumor types [32, 33] , and in breast cancer an additive interaction was observed [34] . Unfortunately, when this combination was evaluated in a phase III trial in metastatic breast cancer, unacceptable cardiac toxicity was reported [35] .
Agents targeting cell division
Paclitaxel impedes the normal breakdown of microtubules during cell division [28] . Preclinical studies in breast cancer cells showed that administration of paclitaxel in addition to trastuzumab had a higher antitumoral activity than the effect of the individual drugs [32, 34, 36] . In the clinical setting, the combination of trastuzumab and paclitaxel showed an improvement in survival compared with paclitaxel alone when evaluated in a randomized clinical trial [35] . In non-small cell lung cancer, cetuximab increased the activity of paclitaxel in cellular and animal models [24] . Vinorelbine is an anti-mitotic agent that has shown a synergistic interaction with trastuzumab in preclinical models, and in the clinic, this combination is a current treatment option for metastatic breast cancer patients [34] .
Antimetabolites
Chemotherapeutic agents such as capecitabine and 5-fluorouracil are thymidylate synthase inhibitors that interrupt the action of this enzyme, blocking the synthesis of thymidine, a nucleotide required for DNA replication [28] . Preclinical studies evaluating capecitabine in combination with trastuzumab showed antagonistic interactions in vitro [34] . Interestingly, the combination of lapatinib with capecitabine was tested in a phase III trial that showed an increase in progression-free survival [35, 37] .
Gemcitabine is a nucleoside analog that replaces cytidine during DNA replication resulting in apoptosis [28] . Combination of anti-EGFR therapies like cetuximab or erlotinib with gemcitabine increased the action of gemcitabine alone using in vivo models of pancreatic cancer. However, these combinations showed limited activity in the clinical setting [38, 39] . These latter two situations exemplify the disparities sometimes observed between preclinical and clinical studies evaluating drug combinations.
Agents targeting the stromal component
It is well established that cellular components of the tumor microenvironment play an important role in sustaining seeding, proliferation, survival, drug penetration, or drug resistance in some types of tumors [40, 41] . This is important, since preclinical work aimed at establishing synergistic interactions is usually performed in vitro and therefore lacks important components of the tumoral tissue that is also amenable of targeting. In order to analyze the contribution of these nontumoral components, several preclinical models have been developed [3] . For instance, co-culture in vitro models in which tumoral cells are grown in the presence of stromal cells have been developed in an attempt to better simulate the in vivo setting [3] . These systems have particularly been used in the evaluation of novel drugs in multiple myeloma, a disease in which the stromal component plays a relevant role in the pathophysiology of the disease [3, 42] . In these assays, the myelomatous plasma cells are placed in co-culture with stromal cells. Often, the action of a drug or a combination of drugs is evaluated on the myelomatous cells cultured alone, or in the presence of the stromal cells, since the latter provide a protective effect which may cause drug resistance. Using adequate analytical techniques, the action of a drug or drug combination can be evaluated on the tumoral cells as well as on the stromal component of these in vitro cultures [42] In addition to this in vitro co-culture model, the use of a more physiological context is often required and this is achieved by using animal models. The prototypical example of agents that require in vivo evaluation of their antitumoral potential is offered by drugs that target angiogenesis. This has been the case for bevacizumab, an antibody against the type A vascular endothelial growth factor [43] . In breast cancer, bevacizumab has been clinically combined with several chemotherapies, including capecitabine, anthracyclines, and taxanes [44] [45] [46] [47] . In vivo models were used to evaluate the interaction between docetaxel and bevacizumab in breast cancer [48] , a regimen that subsequently did not translate into a tangible clinical benefit [46] . Similarly, limited preclinical evidence justified the combination of capecitabine with bevacizumab in breast cancer; a combination that later led to negative results in clinical studies [44, 49] . Indeed, the limited efficacy of the bevacizumab-based combinations in breast cancer observed in recent studies (limited improvement in progression-free survival and no overall survival benefit) led the US Federal Drug Administration to recommend the removal of metastatic breast cancer from the indications for bevacizumab-based therapies [50] . It is noteworthy that some patient did respond to therapy but there was no clear biomarker that could help to identify these responsive patients.
Preclinical studies with bevacizumab were also performed in ovarian, prostate, colon cancer, and glioblastoma, among other tumors [48, [51] [52] [53] [54] . Indeed, in colon cancer and glioblastoma, the clinical activity of bevacizumab seems to be the most relevant [55] [56] [57] [58] .
Targeted agents with chemotherapy: antagonistic combinations
Administration of targeted agents in combination with chemotherapy may fail to produce clinical benefit. Moreover, those combinations can potentially produce undesired effects, such as an antagonistic effect or overlapping toxicities. An example of an antagonistic effect has been reported in the combination of anti-EGFR antibodies with bevacizumab in addition to standard chemotherapy for colorectal cancer. Two phase III trials have reported detrimental interaction of anti-EGFR antibodies with bevacizumab and chemotherapy ( Table 2 ). The PACCE study compared oxaliplatin-based or irinotecan-based chemotherapy plus bevacizumab with or without panitumumab [59] , while the CAIRO2 study compared capecitabine and oxaliplatin chemotherapy plus bevacizumab with or without cetuximab [60] . Interestingly, no clinical benefit was observed in any of the experimental arms for any of the studied endpoints [60] (Table 2 ). An antagonistic interaction between agents was the given explanation for the unexpected results, as no differences in toxicity were observed [61] . Of note, some preclinical studies supported the combination of anti-angiogenic agents with EGFR inhibitors [62, 63] .
Examples of a low therapeutic index due to overlapping toxicities when combining a targeted agent with chemotherapy can be also identified in the literature. For instance, the combination of sorafenib with capecitabine in a randomized phase II trial in metastatic breast cancer led to an unacceptable toxicity profile although potential signs of activity were observed [64] . Also, as mentioned above, the cardiac toxicity found in patients with metastatic breast cancer treated with concurrent trastuzumab and doxorubicin also prevented the approval of this combination in breast cancer [35] .
Optimization of drug combinations using targeted agents
The successful development of combinations of targeted agents and chemotherapy (such as those indicated in Table 1 ) has stimulated the launching of several novel trials aimed at exploiting this strategy. Table 3 shows a description of ongoing phase III trials combining targeted agents with chemotherapy. However, the failure of some combinations to offer clinical benefit raises the question of how to proceed to decrease the attrition rate when trying to clinically develop this type of combinations in oncology.
The fact that cancer is a genetic disease has stimulated much research to identify the genetic alterations present in tumors with the aim of developing strategies to neutralize the effect of such alterations [65] . Ideally, the targeting of the etiopathogenic alterations (such as driver mutations) should result in remission of the disease, as has been demonstrated in the case of chronic myelogenous leukemia (CML). This disease is characterized by the presence of the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22 [66] . This translocation generates a fusion gene which codes for the chimeric cytosolic tyrosine kinase Bcr-Abl, responsible for the pathophysiological consequences of CML. Agents such as imatinib that block the kinase activity of Bcr-Abl are able to control the disease [66] . In this scenario, where a single driver mutation is responsible for the pathophysiological consequences of the Blocks production of clusterin disease, targeting of the mutation should be clinically sufficient to control the disease, and theoretically drug combinations would not be required (Fig. 3a) . The situation appears to be different in most solid tumors. Here, multiple molecular alterations coexist, as has been demonstrated by massive sequencing efforts carried out by different consortia [65] . While these genetic studies are providing massive amounts of data on the molecular alterations present in individual tumors, much work needs to be done to identify the alterations that favor disease progression and resistance to standard therapy. Moreover, it will be necessary to define strategies to neutralize the effect of these alterations. Especially important questions that need to be solved are (1) which altered proteins are really involved in driving tumors and (2) how many of them need to be targeted in order to achieve clinical response. In any case, in this more complex scenario, drug combinations appear a suitable strategy to combat the pathophysiological alterations that drive tumors.
In addition to the targeting of molecular alterations, another efficient antitumoral strategy is the use of agents that block signaling pathways which sustain tumoral cell proliferation or survival. Indications related to that strategy include (1) combination of agents which are expected to act on vertical signaling pathways and (2) combinations of agents that target parallel pathways (Fig. 3b) . The first situation requires the use In the case of multiple etiopathogenic alterations, drug combinations aimed at neutralizing the proteins driving the tumor may be necessary. This would require a critical first step of identification of such alterations to be then targeted by a combination of specific agents. b Strategies to combined drugs in relation to vertical versus parallel pathway inhibition. Vertical inhibition is required to fully inhibit the activity of a pathway. This is required when an oncogenic pathway cannot be fully neutralized by a single agent, and additional agents targeting that pathway have to be used in order to achieve full inhibition. Parallel inhibition refers to the action on several pathways which independently activate oncogenic signals. The vertical or parallel inhibition can be combined with chemotherapy to identify synergistic interactions with an adequate therapeutic index of two or more agents to fully inhibit an oncogenic protein or its signaling pathway. This situation appears when a targeted agent is unable to completely inhibit the master pro-oncogenic protein. This is the case with EGFR small tyrosine kinase inhibitors in non-small cell lung cancers with EGFR mutations [67] . In this scenario, the inhibition of other molecules downstream of the EGFR, such as mTOR, increases the antitumor activity of EGFR-directed tyrosine kinase inhibitors [67] . Another example is the targeting of HER2 with combinations of the anti-HER2 antibodies trastuzumab and pertuzumab [68] , or dual HER2 inhibition using trastuzumab and lapatinib in breast cancer [69] . In those cases, two different drugs which target different domains of the same molecule are used with the purpose of more efficiently acting on oncogenic signals initiated at HER2. Another situation that should also benefit from rational drug combinations is the use of drugs that target several parallel signaling routes involved in the pathophysiology of neoplastic diseases. Concomitant activation of several oncogenic receptor tyrosine kinases has been reported in several tumors, and preclinical studies have shown that their aggregate inhibition increases the antitumor activity as compared to single kinase inhibition [70] [71] [72] . Similarly, inhibition of an activated pathway may cause compensatory activating loops that can be targeted for kinase inhibition [73, 74] . In metastatic melanoma, activation of compensatory pathways after treatment with B-RAF inhibitors can occur through activation of tyrosine kinase receptors or N-RAS upregulation [75, 76] . Table 4 provides information about ongoing studies with combinations of targeted-agents and mechanisms that justify that association.
Given the fact that the combination of multiple targeted agents with chemotherapy could potentially have antagonistic effects or overlapping of toxicities [59, 60] , studies combining targeted agents based on a biological rationale, such as those described above, are not incorporating chemotherapy agents into the regimen. Of note, these combinations should not be synergistic necessarily, but it is expected that they will have more active in tumor cells than in non-transformed normal tissue leading to a broader therapeutic index.
Heterogeneity of cancer and treatment options
Cancer results from the accumulation of genetic and epigenetic alterations that lead to the selection of tumor cells with increased cell proliferation and metastatic potential [77] [78] [79] . When cells acquire certain capabilities like migration or invasion, they disseminate to distant organs where they develop a niche and start proliferating [77] [78] [79] . These distant sides are called metastases and are responsible in most cases for patient death. The classical approach to explain this process is the linear acquisition of mutations; however, its acquisition of mutations conferring metastatic capability can also occur in parallel clones and result in metastatic potential of a given tumor [78] . In addition, cells with self-renewal properties can also concomitantly exist and be responsible for the genesis and maintenance of cancer [80] . This evolutionary process leads to tumor heterogeneity not only within the primary site but at different metastatic sites [79] . In addition, tumor heterogeneity has clinical implications including differential effects on prognosis and drug sensitivity or resistance [77, [79] [80] [81] .
Recent clinical examples have shown a high prevalence of heterogeneity. Large-scale sequencing analyses have observed heterogeneity within individual tumors but also between primary tumors and subsequent local or distant recurrences [82] [83] [84] .
Changes at a DNA level or epigenetic modifications are different between primary tumors and metastases, and can also be different between different metastatic sites. A possible explanation for this heterogeneity is the natural selection of clones secondary to selective pressure in different organ environments. These differences can have clinical implications. For instance in a study in breast cancer comparing primary tumors versus its metastasis, discordance between one or more receptors was found in 37 % of patients and this leaded to a change in treatment for 14 % of them [85] . In this study, the inclusion of a targeted agent like trastuzumab, an antibody against the overexpressed protein HER2, was observed in six patients [85] . What is suggested is that the earlier we intervene to treat a cancer, the less unlikely genetic heterogeneity will develop and this has important consequences over distant relapses and metastases.
There are examples of how treatment can modify the biology of metastatic sites by promoting the clonal selection of non-predominant clones present in the primary tumor. Treatment with chemotherapy can also confer selective advantage for some cells with specific molecular alterations. For instance, treatment with the alkylating agent temozolamide induced a selection of cells with mutations of the MSH6 mismatch repair gene in patients with glioblastoma multiforme [86] . In tumors with mutations at the BRCA2 gene where homologous recombination DNA repair mechanism is impaired, treatment with platinum agents that produce DNA cross-links can increase antitumoral efficacy [87] . However as a compensatory mechanism, tumor cells use other DNA repair mechanisms like the nucleotide excision repair [87] . Therefore, the positive selection of cells that use this mechanism open the possibility of implementing agents against this pathway such as poly ADP ribose polymerase inhibitors (Table 5 ) [88] .
Positive selection can also be observed with targeted agents. Some mutations that were considered as associated with resistance to tyrosine kinase (TK) inhibitors have been recently described as mutations that preexist and that treatment with the drug produced clonal selection. This has been the case for cells with mutations at T315I and E255K at the BCR-ABL gene that existed in a small proportion in treatment-naïve patients with CML and are more prevalent in the post-treatment setting [89] . Similar findings have been described in non-small cell lung cancer (NSCLC) with the presence of T790M mutations at the epidermal growth factor receptor gene in a small proportion of TK inhibitor naïve patients [90] . Microenvironment in metastatic sites is different compared with that of primary tumors, therefore can also modify the therapeutic response to agents. In some tumors, interaction of stromal cells with cancer cells can be crucial for their survival, as is the case in multiple myeloma [40] . Interestingly, in myeloma, agents that target both the stroma and the cancer cell have shown clinical activity, like the proteasome inhibitor bortezomib or the immunomodulatory agent thalidomide [91] . Similar findings have been observed in primary breast cancer where stromal fibroblasts promote tumor growth and angiogenesis [92] . These examples reinforce the concept of targeting the stromal component in addition to the transformed cell.
Conclusions
A limited number of approved therapeutic combinations have been based on synergistic effects and on an adequate therapeutic index evaluation. Targeted agents have generally been combined empirically with the chemotherapy regimen that was considered the standard of care treatment at that time, an approach that is still in used in most ongoing studies (see Table 3 ). Therapeutic index and the potential for antagonistic interactions should be taken in consideration before starting any clinical evaluation, and this is of great importance when combining more than one targeted agent. In this context, combination of drugs should be evaluated in vivo comparing pharmacologic active doses with the HNSTD to anticipate potential doses with clinical activity and to clarify the breadth of the therapeutic index. In addition, ongoing testing of novel compounds using libraries of cells looking for synergistic interactions or signs of activity in specific subgroups [93, 94] is of importance, to try to identify synthetic lethality interactions or mechanisms of resistance to a given targeted agent. This approach can potentially identify synergistic interactions with a wide therapeutic index.
In conclusion, we envision that successful combinations of targeted anticancer agents should be based on strong preclinical data that justify that association and combinations with chemotherapy should only be investigated with prior evidence of synergistic or additive interactions and an adequate therapeutic index.
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